Blog | HemaCare

HemaCare Isolated Immune Cells Bring Quality To Your Doorstep

Mar 31, 2021 10:03:00 AM / by Nancy Andon, MSc

Culturing cells in tissue culture plates_AdobeStock_102697862-1You wanted cell isolation – we delivered!

In 2021, the word isolation tends to have garnered a negative connotation. However, when a cell biologist thinks of isolation, specifically cell isolation, they think of it as a wonderful thing.

After all, isolated cells are a sought-after starting material that allows scientists to dive deeper into their research and accelerate their studies. At HemaCare, we heard your requests and can now deliver isolated immune cells from full leukopak collections to your doorstep!

Working with isolated cell types provides many benefits. It ensures purity and decreases interference from other cell types so that the functions and responses of only the targeted cell population can be effectively examined. It enables scientists to conduct detailed genetic and phenotypic research into specific cell types while increasing the sensitivity of functional assays and other analytical methods. Purified cells are also used directly as starting material for adoptive cell therapies.


Despite the considerable benefits, however, cell isolation can be time-consuming. It can also introduce variability into the research process since purity and viability results differ from lab-to-lab and protocol-to-protocol.

HemaCare’s on-site immune cell isolation service changes all of that. With access to coast-to-coast collection facilities that incorporate state-of-the-art specialized cell collection and processing equipment, and with over 40 years of experience in the apheresis business, our expertise in immune cell isolation is unmatched in the industry.

Like all human-derived cellular products, immune cells are uniquely sensitive to their environment. They are vulnerable to even small temperature changes outside of an ideal range, and responsive to minute differences in growth and freezing media composition. Storage and handling conditions can compromise cell health and viability, impacting downstream function.

HemaCare is committed to leveraging our cell isolation and cryopreservation expertise to bring our clients isolated immune cells that embody the perfect balance of yield and purity. We guarantee that isolated immune cells are free of granulocyte contamination, thus protecting sample integrity. HemaCare immune cell isolation provides:

  • Same-day processing, isolation, and cryopreservation upon collection
  • Integrated workflow solutions
  • Minimal room temperature exposure and no freeze/thaw cycles
  • Best-in-class GMP grade biopreservation and cryopreservation media
  • Rate-controlled cryopreservation
  • Great savings with kit pricing when isolating cells from full leukopaks


Simply put, only the best starting materials produce the best results. At HemaCare, we believe the difference between RUO and GMP-compliant material should never mean compromising on sample quality. HemaCare assesses starting material donors in accordance with all current FDA requirements for allogeneic blood donation. All donors are highly characterized and undergo full infectious disease panel testing. With our on-site same day processing and isolation services, optimized cryopreservation and isolation protocols, stringent quality standards, and rigorous QC testing, customers can expect consistently pure, viable and functional cells. All materials and cell handling procedures are optimized and subject to our rigorous quality management systems.

HemaCare cryopreservation services are second to none. Cryopreservation, done right, protects immune cells from losses of viability and function that can occur during long-term shipping and storage or when unforeseen circumstances delay product processing.

On-site immune cell purification and cryopreservation protect cellular starting materials from non-optimal handling and travel delays while products are shipped from cell collection centers to processing centers and finally to the end-user. HemaCare cell processing methods are optimized and standardized, minimizing the risk of starting material variability. Immune cells are collected, isolated, and cryopreserved on the same day to preserve optimal quality. Starting material variability can also be minimized by isolating matched immune cell types from the same leukapheresis collection. Cryopreserved cells give customers the logistical advantage of having the cells they need on hand, providing a flexible work schedule.

The immunotherapy industry is evolving from being focused primarily on research and development to accommodating rapidly increasing numbers of products in clinical trial and commercial development. As a natural outcome of this shift in focus, the industry as a whole is moving toward using isolated cells rather than more heterogeneous raw materials in order to help save time, reduce starting material variability, and minimize upstream processing steps. The transition to using isolated cell populations as starting material will allow developers to help ensure consistency and more rapid scale up during commercialization. High-quality starting materials prepared using best practices will help smooth that transition.

Topics: Leukopak, Immunotherapy (Immunology)

Nancy Andon, MSc

Written by Nancy Andon, MSc

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts